semaglutide cardiovascular outcomes news 2025 SELECT: Semaglutide's Impact on CVD Events Emerges Quickly Long-Term SELECT Trial: Semaglutide Cuts

The GLP-1 receptor agonist market size was exhibited at USD 36.95 billion in 2023 and is projected to hit around USD 261.19 billion by 2033, growing at a CAGR of 21.6% during the forecast period 2024 to 2033.

It's not a secret that Americans pay far more than people living in other countries for drugs, and those data hold for trendy weight loss and diabetes treatmentsas demand for these therapies | It's not a secret that Americans pay far more than people living in other countries for drugs, and those data hold for trendy weight loss and diabetes treatments like Ozempic and Wegovy.

AN is obesity's metabolic bookend. That connection explains why GLP-1 agonists carry serious risks for those predisposed to AN and with at least one in eight American adults now taking these drugs, the stakes couldn't be higher

learn why strong free cash flow, AA balance sheet, and GLP1 growth support a Buyread the full analysis here.

Low Appetite Meals

While the announcement is focused on pharmaceutical pricing, Ambles approach remains centered on personalized care, accessibility, and ongoing support for every members health journey.